Ann: AGM Presentation, page-33

Dzoanet, as you described it, PTX-200 might be considered as an "ingredient" of Cell-Pryme-M and CellPryme-A.

CellPryme-M is a manufacturing step in the preparation of cell therapies in which PTX-200, as an example of an AKT inhibitor and PH domain inhibitor, may be used in a medium in which cells are cultured.

CellPryme-A is an adjuvant therapy for cellular therapy in which PTX-200 may be used, but likely in combination with a checkpoint inhibitor.

These are new inventions and therefore require new names. I don’t have a problem with that.

If the supposition of PTX playing a crucial role in both CellPryme-M and CellPryme-A is correct, as a shareholder, I’m happy to see the company very cleverly working to derive maximum value from an existing asset.